Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Novartis’ Afinitor recommended for breast cancer in new NICE guidance

Novartis’ Afinitor recommended for breast cancer in new NICE guidance

11th November 2016

Novartis' drug Afinitor has been recommended for routine NHS use as a breast cancer therapy in new draft guidance from the National Institute for Health and Care Excellence (NICE).

The UK regulator has provisionally endorsed the everolimus-based therapy in combination with exemestane as an option for certain patients with HER2-negative, hormone receptor-positive forms of advanced breast cancer.

A once-daily tablet therapy, Afinitor works by stopping a protein that regulates the division of tumour cells and growth of blood vessels from working properly, slowing tumour growth and increasing life expectancy by an average of around four-and-a-half months compared to exemestane alone.

This new guidance comes as part of NICE's push to appraise treatments that were first made available on the UK Cancer Drugs Fund.

Novartis has agreed to provide a significant discount to the NHS, which influenced NICE's decision to provisionally recommend the drug for routine funding on the health service.

Professor Carole Longson, director of the centre for health technology assessment at NICE, said: "The committee concluded that everolimus with exemestane is effective in delaying the growth and spread of breast cancer and, with the revised patient access scheme, is a cost-effective use of NHS resources."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.ADNFCR-8000103-ID-801828226-ADNFCR

We currently have 10 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.